Discounted Cash Flow (DCF) Analysis Levered
CTI BioPharma Corp. (CTIC)
$ 2.565
-0.10 (-3.57%)
Free Cash Flow
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 57.41 | 25.15 | 26.29 | 3.35 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -76.68 | -39.30 | -39.82 | -27.82 | -42.20 | -3.41 | -1.37 | -0.55 | -0.22 | -0.09 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.14 | -0.05 | -0.03 | -0.01 | -0 | -0 | -0 | -0 | -0 | -0 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -76.82 | -39.35 | -39.86 | -27.83 | -42.21 | -3.41 | -1.37 | -0.55 | -0.22 | -0.09 |
Weighted Average Cost Of Capital
| Share price | $ 2.565 |
|---|---|
| Beta | 0.676 |
| Diluted Shares Outstanding | 71.14 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 11.58% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 4.628 |
| Total Debt | 8.91 |
| Total Equity | 182.48 |
| Total Capital | 191.39 |
| Debt Weighting | 4.66 |
| Equity Weighting | 95.34 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2016 Actual | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 57.41 | 25.15 | 26.29 | 3.35 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -76.68 | -39.30 | -39.82 | -27.82 | -42.20 | -3.41 | -1.37 | -0.55 | -0.22 | -0.09 |
| Capital Expenditure | -0.14 | -0.05 | -0.03 | -0.01 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free Cash Flow | -76.82 | -39.35 | -39.86 | -27.83 | -42.21 | -3.41 | -1.37 | -0.55 | -0.22 | -0.09 |
| WACC | ||||||||||
| PV LFCF | -3.25 | -1.25 | -0.48 | -0.18 | -0.07 | |||||
| SUM PV LFCF | -5.22 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 4.95 |
| Free cash flow (t + 1) | -0.09 |
| Terminal Value | -4.62 |
| Present Value of Terminal Value | -3.63 |
Intrinsic Value
| Enterprise Value | -8.86 |
|---|---|
| Net Debt | -31.48 |
| Equity Value | 22.63 |
| Shares Outstanding | 71.14 |
| Equity Value Per Share | 0.32 |